EA035733B9 - Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний - Google Patents

Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний

Info

Publication number
EA035733B9
EA035733B9 EA201890325A EA201890325A EA035733B9 EA 035733 B9 EA035733 B9 EA 035733B9 EA 201890325 A EA201890325 A EA 201890325A EA 201890325 A EA201890325 A EA 201890325A EA 035733 B9 EA035733 B9 EA 035733B9
Authority
EA
Eurasian Patent Office
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Application number
EA201890325A
Other languages
English (en)
Russian (ru)
Other versions
EA201890325A1 (ru
EA035733B1 (ru
Inventor
Грегори Борн
Сяоли Чэн
Брайан Трой Фредерик
Цзе Чжан
Динеш В. Пател
Дэвид Лю
Ашок Бхандари
Original Assignee
Протагонист Терепьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Протагонист Терепьютикс, Инк. filed Critical Протагонист Терепьютикс, Инк.
Publication of EA201890325A1 publication Critical patent/EA201890325A1/ru
Publication of EA035733B1 publication Critical patent/EA035733B1/ru
Publication of EA035733B9 publication Critical patent/EA035733B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201890325A 2015-07-15 2016-07-15 Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний EA035733B9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (3)

Publication Number Publication Date
EA201890325A1 EA201890325A1 (ru) 2018-06-29
EA035733B1 EA035733B1 (ru) 2020-07-31
EA035733B9 true EA035733B9 (ru) 2021-01-14

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890325A EA035733B9 (ru) 2015-07-15 2016-07-15 Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний

Country Status (23)

Country Link
EP (1) EP3341011A4 (ja)
JP (1) JP6858174B2 (ja)
KR (1) KR102513978B1 (ja)
CN (1) CN108348580B (ja)
AU (1) AU2016293619B2 (ja)
BR (1) BR112018000691A2 (ja)
CA (1) CA2991984A1 (ja)
CL (3) CL2018000128A1 (ja)
CO (1) CO2018000349A2 (ja)
CR (1) CR20180029A (ja)
DO (1) DOP2018000010A (ja)
EA (1) EA035733B9 (ja)
EC (1) ECSP18002929A (ja)
HK (2) HK1257747A1 (ja)
IL (1) IL256827A (ja)
MX (1) MX2018000542A (ja)
NI (1) NI201800008A (ja)
PE (1) PE20180571A1 (ja)
PH (1) PH12018500086A1 (ja)
SG (1) SG10201912066SA (ja)
SV (1) SV2018005614A (ja)
UA (1) UA123772C2 (ja)
WO (1) WO2017011820A2 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
CA2955460A1 (en) 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
BR112017006826A2 (pt) 2014-10-01 2017-12-12 Protagonist Therapeutics Inc novos monômeros e dímeros peptídicos a4ss7 antagonistas
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3259269B9 (en) 2015-02-20 2020-03-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
CA3049889A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022540154A (ja) * 2019-07-10 2022-09-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022014011A2 (pt) 2020-01-15 2022-12-20 Janssen Biotech Inc Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias
CN118005737A (zh) * 2020-01-15 2024-05-10 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4247403A1 (en) * 2020-11-20 2023-09-27 JANSSEN Pharmaceutica NV Compositions of peptide inhibitors of interleukin-23 receptor
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN117980320A (zh) * 2021-07-14 2024-05-03 詹森生物科技公司 白介素-23受体的二环肽抑制剂
CA3240982A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US9523073B2 (en) * 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CA2955460A1 (en) 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Also Published As

Publication number Publication date
CN108348580B (zh) 2022-05-10
KR102513978B1 (ko) 2023-03-27
MX2018000542A (es) 2018-06-27
HK1259149A1 (zh) 2019-11-29
CN108348580A (zh) 2018-07-31
IL256827A (en) 2018-03-29
EP3341011A4 (en) 2019-02-20
CL2018000128A1 (es) 2018-06-15
EA201890325A1 (ru) 2018-06-29
AU2016293619A1 (en) 2018-02-01
WO2017011820A3 (en) 2017-02-23
CO2018000349A2 (es) 2018-07-10
JP2018522008A (ja) 2018-08-09
CL2021000343A1 (es) 2021-08-06
SV2018005614A (es) 2018-05-22
DOP2018000010A (es) 2018-03-30
HK1257747A1 (zh) 2019-10-25
EP3341011A2 (en) 2018-07-04
WO2017011820A2 (en) 2017-01-19
CA2991984A1 (en) 2017-01-19
NI201800008A (es) 2018-06-29
CL2018003322A1 (es) 2019-01-18
ECSP18002929A (es) 2018-03-31
PE20180571A1 (es) 2018-04-04
PH12018500086A1 (en) 2018-07-30
CR20180029A (es) 2018-06-05
JP6858174B2 (ja) 2021-04-14
UA123772C2 (uk) 2021-06-02
BR112018000691A2 (pt) 2018-09-18
AU2016293619B2 (en) 2021-02-25
KR20180030663A (ko) 2018-03-23
EA035733B1 (ru) 2020-07-31
SG10201912066SA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MD3360558T2 (ro) Compoziții care cuprind tulpini bacteriene
MX2023008693A (es) Polinucleotidos moduladores.
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
MD3204025T2 (ro) Compoziții care conțin tulpini bacteriene
MD3650033T2 (ro) Compoziții conţinând tulpini bacteriene
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201791937A1 (ru) Противовоспалительные полипептиды
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM